-$0.54 Earnings Per Share Expected for Aptinyx Inc (APTX) This Quarter

Wall Street analysts predict that Aptinyx Inc (NASDAQ:APTX) will report earnings of ($0.54) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aptinyx’s earnings. The firm is scheduled to issue its next quarterly earnings report before the market opens on Thursday, March 21st.

On average, analysts expect that Aptinyx will report full year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($2.74) to ($2.66). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.24) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Aptinyx.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated a “buy” rating and issued a $40.00 price target on shares of Aptinyx in a research report on Monday, December 3rd. Leerink Swann dropped their price target on Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, January 17th. JPMorgan Chase & Co. cut Aptinyx from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $30.00 to $8.00 in a research report on Thursday, January 17th. BMO Capital Markets dropped their price target on Aptinyx to $18.00 and set an “outperform” rating on the stock in a research report on Friday, January 18th. Finally, Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Monday, January 21st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $18.80.



In other Aptinyx news, Director Robert J. Hombach bought 25,000 shares of the company’s stock in a transaction on Friday, January 25th. The shares were bought at an average price of $5.53 per share, for a total transaction of $138,250.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Ashish Khanna bought 10,000 shares of the company’s stock in a transaction on Friday, January 18th. The shares were acquired at an average price of $5.45 per share, for a total transaction of $54,500.00. The disclosure for this purchase can be found here. Insiders purchased a total of 36,050 shares of company stock worth $198,284 in the last 90 days.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APTX. Great West Life Assurance Co. Can acquired a new position in Aptinyx during the 4th quarter worth approximately $40,000. Legal & General Group Plc acquired a new position in Aptinyx during the 3rd quarter worth approximately $58,000. Metropolitan Life Insurance Co. NY increased its position in Aptinyx by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after purchasing an additional 5,652 shares during the period. Barclays PLC increased its position in Aptinyx by 87.1% during the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after purchasing an additional 4,340 shares during the period. Finally, Wells Fargo & Company MN acquired a new position in Aptinyx during the 3rd quarter worth approximately $185,000. Institutional investors own 63.11% of the company’s stock.

Shares of Aptinyx stock traded down $0.08 on Wednesday, hitting $4.01. The stock had a trading volume of 351,000 shares, compared to its average volume of 398,341. Aptinyx has a 52-week low of $3.90 and a 52-week high of $32.25.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Read More: What are the risks of holding treasury bonds?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.